VEGFR2

VEGFR2 is the vascular endothelial growth factor receptor 2, a tyrosine-kinase receptor on vascular endothelial cells. Activation triggers Akt phosphorylation and endothelial nitric oxide synthase signalling, driving new-vessel formation. It is the most-cited receptor target in BPC-157 angiogenic-mechanism research.

Definition

Vascular endothelial growth factor receptor 2 (VEGFR2, also designated KDR in human gene nomenclature and Flk-1 in mouse) is a receptor tyrosine kinase expressed on vascular endothelial cells. Binding of vascular endothelial growth factor (VEGF) ligands triggers receptor dimerisation and autophosphorylation, which in turn activates several downstream signalling pathways. The most characterised cascade for new-vessel-formation research runs through Akt phosphorylation to endothelial nitric oxide synthase (eNOS) activation, raising nitric oxide output and contributing to angiogenic responses in tissue-repair models.

BPC-157 research documents activation of VEGFR2 in vascular endothelial cells with receptor up-regulation following exposure (PMID 27847966). The VEGFR2-Akt-eNOS cascade is the most-replicated mechanistic finding in the BPC-157 literature and is the anchor framing for the compound’s documented effects on new-vessel formation and tissue perfusion in preclinical wound-healing models.

How VEGFR2 is studied in peptide research

VEGFR2 signalling appears across multiple peptide-research literatures because angiogenesis is implicated in tissue-repair, cardiovascular, oncology, and metabolic-disease research. In peptide-research contexts specifically, the receptor is most commonly studied as a downstream target of compounds whose angiogenic or perfusion-modulating activity is being characterised. Standard experimental approaches include endothelial-cell culture with receptor-phosphorylation assays, in-vivo wound-healing models with histological scoring, and ischemia-reperfusion models examining collateral circulation recruitment.

For BPC-157 specifically, VEGFR2 engagement was documented by Hsieh et al. (2017) using vascular endothelial cell culture, with downstream Akt phosphorylation and eNOS activation confirmed. Subsequent reviews (PMID 23782145, PMID 23755725) synthesise the receptor-engagement and nitric-oxide-system findings into a unified angiogenic model. Major-vessel-occlusion research (PMID 35125818) extends the framing to collateral-pathway recruitment in ischemic-stress contexts.

Related terms

• BPC-157
• Akt signalling pathway
• eNOS / endothelial nitric oxide synthase
• Angiogenesis
• VEGF / vascular endothelial growth factor
• Tyrosine kinase receptor

Compounds where VEGFR2 appears in the mechanism literature

• BPC-157 — VEGFR2 activation is the most-cited mechanism in the preclinical literature
• TB-500 — angiogenic signalling via integrin-linked kinase pathways, mechanistically distinct from VEGFR2 but with overlapping downstream new-vessel-formation outcomes
• GHK-Cu — angiogenic and ECM-remodelling research with copper-dependent signalling, studied separately from VEGFR2 but in adjacent tissue-repair contexts

References

1. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
2. Seiwerth S et al. BPC 157 and blood vessels. Curr Pharm Des 2014;20(7):1121-1125. [PMID 23782145]
3. Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
4. Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World Journal of Gastroenterology 2022. [PMID 35125818]

Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.